NBIX - Neurocrine Biosciences executive discloses sale of over 10K shares
2023-11-30 09:53:30 ET
More on Neurocrine Biosciences
- Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success
- Neurocrine settles all patent disputes related to movement disorder therapy
- Neurocrine reports Phase 2 study failures for two drug candidates
For further details see:
Neurocrine Biosciences executive discloses sale of over 10K shares